Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP: 1.Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

Now Viewing

EP: 2.Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP: 3.Outcomes from NATALEE and MonarchE

EP: 4.Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP: 5.Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

EP: 6.Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

EP: 7.Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

EP: 8.Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

EP: 9.Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

EP: 10.How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

EP: 11.Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

EP: 12.Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

EP: 13.ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following:

• Abemaciclib is recommended by NCCN in this setting based on the monarchE trial, which recently released its 5-year long-term data in January.
  • Describe the updated survival data, including both invasive disease-free survival and overall survival. How have these survival rates evolved with each annual analysis?
  • Please highlight the follow-up time of patients.
• Are there specific subgroups of patients within the monarchE trial who derived particular benefit from the addition of abemaciclib?